DEMI-REGROTON Drug Patent Profile
✉ Email this page to a colleague
When do Demi-regroton patents expire, and when can generic versions of Demi-regroton launch?
Demi-regroton is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in DEMI-REGROTON is chlorthalidone; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the chlorthalidone; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEMI-REGROTON?
- What are the global sales for DEMI-REGROTON?
- What is Average Wholesale Price for DEMI-REGROTON?
Summary for DEMI-REGROTON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| DailyMed Link: | DEMI-REGROTON at DailyMed |
US Patents and Regulatory Information for DEMI-REGROTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | DEMI-REGROTON | chlorthalidone; reserpine | TABLET;ORAL | 015103-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
